DEPO Share Price

Open 5.96 Change Price %
High 5.98 1 Day -0.05 -0.83
Low 5.83 1 Week -0.47 -7.33
Close 5.94 1 Month -0.27 -4.35
Volume 1020613 1 Year -18.87 -76.06
52 Week High 27.02
52 Week Low 5.81
DEPO Important Levels
Resistance 2 6.08
Resistance 1 6.02
Pivot 5.92
Support 1 5.86
Support 2 5.80
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
AAPL 156.07 -1.68%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
ALNY 113.84 51.71%
LOCM 0.09 50.00%
VALV 0.03 50.00%
HAUP 0.08 33.33%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LTRE 2.80 20.69%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
AMCF 0.01 -80.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
ORIG 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Depomed, Inc. (NASDAQ: DEPO)

DEPO Technical Analysis 5
As on 20th Sep 2017 DEPO Share Price closed @ 5.94 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 14.00 & Strong Sell for SHORT-TERM with Stoploss of 8.05 we also expect STOCK to react on Following IMPORTANT LEVELS.
DEPO Target for September
1st Target up-side 8.59
2nd Target up-side 10.34
3rd Target up-side 12.1
1st Target down-side 3.57
2nd Target down-side 1.82
3rd Target down-side 0.06
DEPO Other Details
Segment EQ
Market Capital 332246432.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.depomedinc.com
DEPO Address
DEPO
7999 Gateway Boulevard
Suite 300
Newark, CA 94560
United States
Phone: 510-744-8000
Fax: 510-744-8001
DEPO Latest News
Interactive Technical Analysis Chart Depomed, Inc. ( DEPO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Depomed, Inc.
DEPO Business Profile
Depomed, Inc. (Depomed) is a specialty pharmaceutical company initially focused on neurology, pain and other diseases of the central nervous system. In January 2011, the United States Food and Drug Administration (FDA) approved Gralise (gabapentin) once-daily tablets for the management of postherpetic neuralgia. The Company is developing and commercializing a number of pharmaceutical products for neurology, pain and other central nervous system conditions and diseases. The Company�s products include Gralise, Glumetza, Serada and DM-1992. Gralise (gabapentin) is its once-daily formulation of gabapentin for the management of postherpetic neuralgia (PHN). Glumetza is the Company's once-daily treatment for adults with type 2 diabetes that is commercialized in the United States by Santarus, Inc. (Santarus). In June 2012, the Company acquired all rights to Zipsor (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc.